Fundraising FoxBAM Elevate — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)
Co-investorsAccess BiotechnologyViking GlobalAndreessen HorowitzBay City CapitalCommodore CapitalEIR Ventures+8 more
Ambros Therapeutics is a therapeutics company.
BiotechHealthtechSan Diego, US
Joseph (Jay) Hagan(President and Chief Executive Officer)
Co-investorsLifeSci Venture PartnersRA CapitalJanus Henderson InvestorsPatient Square Capital
Crusoe builds energy-first AI infrastructure, using innovative and renewable energy sources to power hyperscale AI factories and a cloud platform for AI workloads.
AI & Machine LearningCloud ComputingData & InfrastructureEnergyDenver, US
Cully Cavness(Founder)inChase Lochmiller(Founder)inCharles Cavness(Executive Officer, Director)Matthew DeNezza(Executive Officer)inJamey Seely(Executive Officer)inMichael Gordon(Executive Officer)in
Co-investorsAbstract VenturesACTIVATE CAPITAL PARTNERSAdvaita CapitalAir Street CapitalAkkaAlkeon Innovation+74 more
Forterra develops autonomous weapons, sensors, and battlefield systems using distributed control networks for defense operations.
AI & Machine LearningDefense TechRoboticsClarksburg, US
Alberto Lacaze(President and Founder; Chairman of the Board)inJoseph Putney(Chief Technology Officer)inJosh Araujo(Chief Executive Officer)
Co-investors645 VenturesCollaborative FundCRESCENT COVE CAPITALEnlightenment CapitalGlynn Capital ManagementLitquidity Ventures+13 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.